Skip to content

Safety and Efficacy assessment of Product on skin

To evaluate the comedogenic effect of skincare formulation Photostable new formulation-OCTCB on healthy human female subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042840
Enrollment
36
Registered
2022-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Photostable new formulation-OCTCB: Product will be applied on the whole face, once in a day for a period of 28 days Control Intervention1: NIL: Not applicable

Sponsors

Sun Pharmaceutical Industries Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Indian female subjects 2 Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup) 3 Between 18 and 35 years of age. 4 Skin is healthy on the studied anatomic unit (e.g. free of eczema, wounds, inflammatory scar) 5 Having oily or mixed oily skin type on the face (Visual assessment by dermatologist)

Exclusion criteria

Exclusion criteria: 1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having a progressive asthma (either under treatment or last fit in the last 2 years) 6 Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis) 7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8 Being epileptic. 9 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 10 Having cutaneous hypersensitivity. 11 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 12 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months. 13 Having changed her cosmetic habits except those required by the protocol in the 14 days preceding the start of the study on the studied anatomic unit. 14 Having applied a cosmetic product (included make-up) on the studied areas the first day of the study (only face cleaned with water is accepted) 15 Having applied hair oil during the entire duration of the study. 16 In the previous 6 months -Having started, changed or stopped a hormonal treatment (e.g. hormonal contraception, cyproterone acetate) -Having taken an oral retinoid-based treatment -Having undergone a physical (e.g., phototherapy, laser) or chemical (peeling) treatment for acne 17 In the previous 1 month -Having had a local benzoyl-peroxide-based treatment or a local retinoid-based treatment -Having had an oral treatment with a base of cimetidine, zinc (zinc gluconate) or spironolactone 18 In the previous 2 weeks -Having applied cosmetic products with anti-seborrheic aims or cosmetics for oily skin -Having had oral or local antibiotic treatment for acne 19 In the previous 1 week -Having had beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask) -Having a suntanned skin on the studied areas which could interfere with the evaluations of the stud

Design outcomes

Primary

MeasureTime frame
Percent reduction in total number of comedonesTimepoint: 14days, 28days

Secondary

MeasureTime frame
Percent reduction in sebum, safety of ProductTimepoint: 14days, 28days

Countries

India

Contacts

Public ContactMr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

raji@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026